Infections with mould pathogens have emerged as an increasing risk faced by patients under sustained immunosuppression. Species of the Aspergillus family account for most of these infections and in particular Aspergillus fumigatus can be regarded as the most important airborne-pathogenic fungus. The improvement in transplant medicine and the therapy of hematological malignancies is often complicated by the threat of invasive aspergillosis. Specific diagnostics are still limited, as are the possibilities of therapeutic intervention. Hence, invasive aspergillosis is still associated with a high mortality rate that ranges from 30 % to 90 %. In recent years, considerable progress has been made in understanding the genetics of A. fumigatus and molecular techniques for the manipulation of the fungus have been developed. Molecular genetics offers not only approaches for the detailed characterization of gene products that appear to be key components of the infection process but also selection strategies that combine classical genetics and molecular biology to identify virulence determinants of A. fumigatus. The review discusses aspects of the current knowledge of the infection process, mechanisms of protection of the fungus against immune effector cells, and virulence determinants of A. fumigatus.
No Supplementary Data
No Article Media
cAMP signal transduction;
Document Type: Review Article
Department of Molecular and Applied Microbiology, Leibniz-Institute for Natural Product Research and Infection Biology - HKI-, Beutenbergstrasse 11a, D-07745 Jena, Germany.
Publication date: December 1, 2005
More about this publication?
Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites